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Abstract 
Review on del(X)(p22.33p22.33) or 
del(Y)(p11.32p11.32), with data on the genes 
involved, and clinics. 
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PR2Y8/CRLF2 rearrangement, PR2Y8/CRLF2 
fusion, PAR1 deletion 
Clinics and pathology 
Disease 
Provisional entity: B-lymphoblastic 
leukemia/lymphoma, BCR-ABL1-like (Arber et al., 
2016) 
Etiology 
Among positive patients the PR2Y8/CRLF2 
rearrangement has been detected in different 
proportions of cells, in principal clones and in minor 
subclones. Original major clones may persist, 
disappear, or revert to a minor clone; the minor 
clones may evolve into a major clone or loss, 
continue or substitute by a clone with different 
breakpoint. Based on this, it has been proposed that 
PR2Y8/CRLF2 is not a driver abnormality in the 
process of leukemogenesis. Instead, it is a secondary 
lesion and requires concomitant mutations to 
become functionally important. The presence of 
acquire CRLF2 rearrangements in constitutional 
trisomy 21, and the coexistence of the 
PR2Y8/CRLF2  and iAMP21  in non-Down 
syndrome B-cell precursor (BCP) acute 
lymphoblastic leukemia (ALL), also suggest that 
CRLF2 rearrangements requires cooperating 
mutations to activate JAK/STAT and PI3K/mTOR 
pathways (Morak et al., 2012). 
Epidemiology 
PR2Y8/CRLF2 positive patients are included in the 
Ph-like BCP-ALL subgroup, based on its 
characteristic gene expression signature (Arber et al., 
2016). The prevalence of this subgroup is associated 
with age, high-risk stratification and ethnicity 
(Harvey et al., 2010). It presents in about 10% of 
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standard-risk childhood ALL, and in >25% of young 
adults; CRLF2 is the most frequent deregulated gene 
in the Ph-like subgroup. Overexpression of CRLF2 
results in constitutive JAK/STAT activation and 
cytokine-independent growth (Roberts et al., 2015). 
In the total of BCP-ALL patients 6% present over-
expression of CRLF2, this deregulation is more 
prevalent among Down syndrome patients (54%). In 
an unselected cohort of pediatric patients, the 
Medical Research Council (MRC) found 
predominance of PR2Y8/CRLF2 (5%) in contrast to 
IGH/CRLF2 (1%). In comparison, the Children's 
Oncology Group (COG) observed that IGH/CRLF2 
is twice as prevalent as PR2Y8/CRLF2 (Ensor et al., 
2011); this variability could be explained by the 
selection of high risk ALL patients analysed in this 
study, including a high proportion of older patients 
and Hispanic patients, who are 5 times more possible 
to have CRLF2 abnormalities compared with 
patients with other ethnicities. In children with BCP-
ALL and Down syndrome PR2Y8/CRLF2 was 
identified in 54.5% of cases (Mullighan et al., 2009). 
In adults with BCP-ALL the prevalence of Ph-like is 
>20%, of this group, the IGH/CRLF2 (57.6%) is 
more prevalent than PR2Y8/CRLF2 (21.2%) 
(Roberts et al., 2017). In general, IGH/CRLF2 
patients are older than PR2Y8/CRLF2 patients. 
Clinics 
ALL with BCP immunophenotype with 
rearrangement involving a cytokine receptor, 
included in the BCR-ABL1-like ALL subgroup. 
Treatment 
The PR2Y8/CRLF2 rearrangement results in kinase-
activating lesion that causes the constitutive 
activation of the JAK/STAT signalling pathway. 
Therefore, patients with PR2Y8/CRLF2 ALL could 
benefit from the treatment with clinically approved 
tyrosine kinase inhibitors such as Ruxolitinib, which 
target these pathways. The treatment of these 
patients with the relevant tyrosine kinase inhibitor 
could potentially improve their survival (Harrison, 
2013). 
Prognosis 
In different cohorts of children with high risk ALL, 
the presence of CRLF2 alterations have been 
associated with poor clinical outcome. However, not 
in all the study groups have been found positive 
correlations. The different treatment protocols, not 
standardized methods for diagnosis of CRLF2 
alterations or over-expression, and limited 
prospective studies for analysing prognostic value 
are source of bias. A meta-analysis study including 
5945 patients of seven different studies analysed the 
association between CRLF2 alterations and survival 
of children with ALL, the results showed that 
CRLF2 deregulation predicts poor prognosis. In 
adults, the outcome of patients with Ph-like ALL is 
inferior compared with the outcome of patients with 
non-Ph-like ALL, excluding BCR/ABL1 and MLL 
positive cases (Roberts et al., 2017).  
 
It is expected that PR2Y8/CRLF2 positive clones 
contribute to disease progression. However, in 
children it has been found heterogeneity in 
PR2Y8/CRLF2 clone sizes, and no participation in 
relapses if the size is very small at diagnosis. In part, 
these may be the basis of the controversies about the 
prognostic value of this rearrangement and the over-
expression of CRLF2 as risk markers. A revision of 
these parameters should be done. 
Disease 
T-lymphoblastic leukemia/lymphoma (T-ALL) 
Note 
It has been reported CRLF2 over-expression in T-
ALL patients: however, PR2Y8/CRLF2 has not been 
found in these cases. Deregulation of CRLF2 in this 
entity is considered a poor prognosis marker (Palmi 
et al., 2016). 
Cytogenetics 
Cytogenetics molecular 
del(X)(p22.33p22.33) or del(Y)(p11.32p11.32) 
PR2Y8/CRLF2 is a cryptic rearrangement, results 
from intrachromosomal deletions within the 
pseudoautosomal region (PAR1) located in the p arm 
of the sex chromosomes (Harrison, 2013). Until 
now, this abnormality has not been found with the 
recurrent cytogenetic abnormalities commonly 
observed in BCP-ALL, but can occur with the 
iAMP21 or in high hyperdiploid patients; one patient 
has been reported with the coexistence of 
PR2Y8/CRLF2 and IGH/CRLF2 (Harvey et al., 
2010). A novel CRLF2 rearrangement formed with a 
gene of the PAR1 region has been described 
(CSF2RA/CRLF2) (Yano et al., 2015). The IKZF1 
deletions may be also observed, but are less 
prevalent than IGH/CRLF2 (Ensor et al., 2011). 
JAK1, JAK2 and JAK3 mutations are found in 10 % 
of high-risk BCP-ALL cases (Mullighan et al., 
2009). 
In Down syndrome patients, +X, and del(9)(p22) 
have been found in PR2Y8/CRLF2 positive cases 
(Figure 1). JAK mutations are present up to 28% of 
patients; JAK2 mutations in the pseudokinase 
domain are the most common (Mullighan et al., 
2009). 
 
FISH in interphases with the PR2Y8/CRLF2 (PAR 
1) deletion probe (Cytocell Aquarius) on a bone 
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marrow sample of a female patient with Down 
syndrome. A) The expected two normal signals 
(red/green): B) One normal signal (red/green) and 
one corresponding to the PAR1 deletion (green with 
white arrow). C) One normal signal (red/green) and 
two abnormal signals (green with white arrows) 
which indicate the presence of two X chromosomes 
with the PAR1 deletion. 
Genes involved and 
proteins 





It is located at the PAR1 of chromosome X, 
Xp22.33, and chromosome Y, Yp11. 
Other names and symbols: Thymic Stromal 
Lymphopoietin Protein Receptor, TSLP Receptor, 
IL-XR, TSLPR, CRL2, Thymic Stromal-Derived 
Lymphopoietin Receptor, Cytokine Receptor-Like 
2. 
DNA/RNA 
The genomic location of CRLF2 gene in 
chromosome X starts in 1,187, 549 bp from pter, and 
ends in 1, 212, 815 bp from pter. The size is 25, 267 
bases, with minus strand orientation NC_018934. 
 
Chromosomal location of the CRLF2 gene. 
Protein 
The cytokine receptor-like factor 2 has a size of 371 
amino acids, with a molecular mass of 42013 
Daltons. Cytokine receptor-like factor 2 is a 
transmembrane protein with an extracellular domain 
of 210 residues, and an intracellular domain of 119 
residues (Zhang et al., 2001). CRLF2 
heterodimerizes with IL7R constituting a functional 
receptor (Rochman et al., 2010; Bugarin C et al., 
2015). 
Somatic mutations 
The CRLF2 711T>G (Phe232Cys) mutation has 
been found in ALL blasts. The CRLF2 Phe232 
residue is near to the junction of the extracellular and 
transmembrane domains. The Phe232Cys mutation 
confers a constitutive dimerization through the 
cysteine residues inducing the growth of cells. This 
mutation also promotes the up-regulation of 
transcriptional targets downstream of the 
JAK/STAT pathway (Yoda et al., 2010). 
P2RY8 (purinergic receptor P2Y, G-




P2RY8 is located at the pseudoautosomal region 1 
(PAR1) of chromosome X, Xp22.33 and 
chromosome Y, Yp11. 
Other names and symbols: purinergic receptor P2Y, 
G-protein coupled, 8, P2Y8, G-protein coupled 
purinergic receptor P2Y8, P2Y purinoceptor 8. 
DNA/RNA 
The genomic location of P2RY8 gene in 
chromosome X starts in 1,462, 572 bp from pter and 
ends in 1,537,506 bp from pter. The size is 74,935 
bases, with minus strand orientation NC_000023. 
 
Chromosomal location of the P2RY8 gene. 
del(X)(p22p22); del(Y) P2RY8/CRLF2  
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Protein 
The P2Y purinoceptor 8 protein has a size of 359 
amino acids, with a molecular mass of 40635 
Daltons. 




The PR2Y8/CRLF2 rearrangement results from an 
interstitial microdeletion involving the PAR1, which 
is located in the short arm of both sex chromosomes. 
This deletion causes the CRLF2 overexpression 
through the juxtaposition of the entire coding 
sequence of CRLF2 with the first non-coding exon 
of P2RY8, and their transcriptional control elements 
that are highly active in lymphoid cells (Morak et al., 
2016; Vesely et al., 2016; Ensor et al; 2016; 
Mullighan et al; 2009). 
 
Description 
The PAR1 deletion measures approximately 320 Kb 
and deletes the complete coding sequence of P2RY8 
along with ASMTL, SLC25A6, IL3RA and 
CSF2RA genes, bringing together the first exon of 
P2RY8 to exon 1 of CRLF2. The breakpoints of the 
deletion are highly conserved and are located 3.4 Kb 
upstream of the CRLF2 exon 1 and 0.3-1 Kb distal 
to P2RY8 exon 1 (Mullighan et al., 2009). Two new 
alternative breakpoints have been described, 2.1 Kb 
and 0.1 Kb upstream of CRLF2 exon 1, but in all 
cases the deletion place the full CRLF2 open reading 
frame under transcriptional control of the P2RY8 
promoter (Morak et al., 2016). The presence of 
recombination signal sequences immediately 
internal to the deletion breakpoints suggests that the 
PAR1 deletion may arise as a result of aberrant 
activity of the RAG recombinases, this phenomenon 
has been described for other chromosomal 
rearrangements in B- ALL (Mullighan et al; 2009). 
Transcript 
The chimeric transcript contains the 5-UTR region 
of P2RY8 joined to exon 1 of CRLF2, prior to the 
transcription start codon (Hertzberg et al., 2016). 
The PR2Y8 5-UTR region measures approximately 
226 bp, and the open reading frame of CRLF2, which 
is approximately of 1116 bp, remains complete; 
therefore the chimeric transcript size is 1342 bp (Yap 
et al., 2016). 
Detection 
The PR2Y8/CRLF2 positive cases can be detected at 
genomic level by long range PCR or MLPA 
techniques using genomic DNA extracted from 
leukemic cells, however, these assays only reveal the 
presence of the rearrangement. On the other hand, 
FISH assay informs about the proportion of 
abnormal cells, it has been designed deletion probes 
for covering the telomeric end of P2RY8 and a 
region distal to the gene, and a control probe that 
covers a region of the proximal side of P2RY8 
(Morak et al., 2016). At RNA level, RT-PCR can 
confirm the presence of chimeric transcripts. The  
 
overexpression of CRLF2 can be measured by qRT-
PCR using different methods of absolute and relative 
measurement (Mullighan et al; 2009). 
Fusion protein 
Oncogenesis 
The overexpression of CRLF2 produced by the 
PR2Y8/CRLF2 rearrangement causes the 
constitutive activation of JAK/SAT signaling and the 
PI3K/mTOR, Ras, MAPK and Bcl-2 downstream 
related pathways in the leukemic blast.  These 
signaling pathways have a central role in the 
regulation of the cell proliferation, survival, 
differentiation and immune response; hence its 
malfunction contributes to the leukemic 
transformation (Roberts KG et al., 2015). 
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